Premium
Reliability of the Charcot‐Marie‐Tooth functional outcome measure
Author(s) -
Bray Paula,
Cornett Kayla M. D.,
Estilow Timothy,
Pareyson Davide,
Zuccarino Riccardo,
Skorupinska Mariola,
Pipis Menelaos,
Sowden Janet E.,
Scherer Steven,
Reilly Mary M.,
Shy Michael E.,
Herrmann David N.,
Burns Joshua,
Eichinger Katy J.
Publication year - 2020
Publication title -
journal of the peripheral nervous system
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1
H-Index - 67
eISSN - 1529-8027
pISSN - 1085-9489
DOI - 10.1111/jns.12406
Subject(s) - reliability (semiconductor) , internal consistency , convergent validity , medicine , clinical trial , physical therapy , psychology , clinical psychology , gerontology , psychometrics , power (physics) , physics , quantum mechanics
The CMT‐FOM is a 13‐item clinical outcome assessment (COA) that measures physical ability in adults with Charcot‐Marie‐Tooth disease (CMT). Test‐retest reliability, internal consistency and convergent validity have been established for the CMT‐FOM. This current study sought to establish inter‐rater reliability. Following an in‐person training of six international clinical evaluators we recruited 10 participants with genetically diagnosed CMT1A, (aged 18‐74 years, 6 female). Participants were evaluated using the CMT‐FOM over 2 days. Participants were given at least a 3 hour rest between evaluations, and were assessed twice each day. Following the provision of training by master trainers, all 13 items of the CMT‐FOM exhibited excellent inter‐rater reliability for raw scores (ICC 1,1 0.825‐0.989) and z‐scores (ICC 1,1 0.762‐0.969). Reliability of the CMT‐FOM total score was excellent (ICC 1,1 0.983, 95% CI 0.958‐0.995). The CMT‐FOM is a reliable COA used by clinical evaluators internationally. The next steps are to establish further validation through psychometric evaluation of the CMT‐FOM in the Accelerate Clinical Trials in CMT (ACT‐CMT) study.